Axa
JUNO

Axa’s Juno Therapeutics, Inc. JUNO Stock Holding History

Axa’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-32,279
Closed -$1.72M – 1545
2015
Q2 		$1.72M Hold
32,279
– – 0.01% 825
2015
Q1 		$1.96M Buy
32,279
+2,279
+8% +$111K 0.01% 811
2014
Q4 		$1.57M Buy
+30,000
New +$1.34M 0.01% 857

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM

Axa's JUNO Position: Q3 2015 in Review

Axa sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2015, closing a stake of 32,279 shares — an estimated $1.72M sold.

Axa first reported a position in JUNO in Q4 2014 and held it in 3 quarters. The position peaked at $1.96M in Q1 2015. 132 funds tracked by Wall St. Rank hold JUNO as of Q3 2015.

  • Axa reported no remaining Juno Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Axa sold 32,279 Juno Therapeutics, Inc. shares in Q3 2015, an estimated $1.72M.
  • Axa first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
  • Axa's Juno Therapeutics, Inc. position peaked at $1.96M in Q1 2015.
  • 132 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2015.

Based on Axa's 13F filing for Q3 2015, filed 13 Nov 2015.